超越他汀类药物治疗：糖尿病患者残余风险管理的综述。
Beyond statin therapy: a review of the management of residual risk in diabetes mellitus.
机构信息
Department of Endocrinology, St Columcille's Hospital, Loughlinstown, Co. Dublin, Ireland.
出版信息
J R Soc Med. 2010 Sep;103(9):357-62. doi: 10.1258/jrsm.2010.100033.
Abstract
Total cholesterol and low-density lipoprotein (LDL) cholesterol exhibit an independent, strong, continuous correlation with cardiovascular events. The effectiveness of hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in the treatment and prevention of atherosclerosis is well-established. However, despite the lowering of LDL targets and the increased use of statins, patients with type 2 diabetes mellitus (DM) continue to experience a higher proportion of adverse coronary artery disease events. This is as a result of an atherogenic dyslipidaemia, characterized by low levels of high-density lipoprotein and elevated plasma triglyceride concentrations, often with high levels of cholesterol-rich remnant particles. This article will review dyslipidaemia and its role in DM, and will discuss available treatment modalities that address residual cardiovascular risk in this disease.
摘要
总胆固醇和低密度脂蛋白（LDL）胆固醇与心血管事件呈独立、强、连续相关。羟甲基戊二酰辅酶 A 还原酶抑制剂（他汀类药物）在动脉粥样硬化的治疗和预防中的有效性已得到充分证实。然而，尽管降低了 LDL 目标并增加了他汀类药物的使用，2 型糖尿病（DM）患者仍继续经历更高比例的不良冠状动脉疾病事件。这是由于致动脉粥样硬化的血脂异常，其特征是高密度脂蛋白水平低和血浆甘油三酯浓度升高，通常伴有富含胆固醇的残粒水平升高。本文将回顾血脂异常及其在 DM 中的作用，并讨论可用于解决该疾病剩余心血管风险的治疗方法。
相似文献
1
Beyond statin therapy: a review of the management of residual risk in diabetes mellitus.
J R Soc Med. 2010 Sep;103(9):357-62. doi: 10.1258/jrsm.2010.100033.
2
Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Adv Cardiol. 2008;45:127-153. doi: 10.1159/000115192.
3
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Cardiovasc Diabetol. 2006 Sep 26;5:20. doi: 10.1186/1475-2840-5-20.
4
Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
Am J Cardiol. 2005 Nov 7;96(9A):20K-27K; discussion 34K-35K. doi: 10.1016/j.amjcard.2005.08.004. Epub 2005 Sep 21.
5
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
Vasc Health Risk Manag. 2009;5:793-9. doi: 10.2147/vhrm.s5684. Epub 2009 Sep 24.
6
Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events.
Am J Med. 2010 Oct;123(10):892-8. doi: 10.1016/j.amjmed.2010.03.024.
7
Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9.
8
[Global therapy of diabetic dyslipidemia: benefits and new therapeutic approaches].
Med Clin (Barc). 2010 Apr 3;134(9):406-11. doi: 10.1016/j.medcli.2009.10.010. Epub 2010 Jan 4.
9
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Am J Cardiovasc Drugs. 2005;5(6):379-87. doi: 10.2165/00129784-200505060-00005.
10
Diabetic dyslipidemia: a practical guide to therapy.
J Fam Pract. 2008 Jun;57(6):377-88.
引用本文的文献
1
Impact of baseline and trajectory of the atherogenic index of plasma on incident diabetic kidney disease and retinopathy in participants with type 2 diabetes: a longitudinal cohort study.
Lipids Health Dis. 2024 Jan 11;23(1):11. doi: 10.1186/s12944-024-02003-5.
2
High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine.
Front Cardiovasc Med. 2023 Oct 16;10:1264319. doi: 10.3389/fcvm.2023.1264319. eCollection 2023.
3
mediates lipid uptake by suppressing PCSK9 transcription and increasing LDL receptor in human liver cells.
Saudi J Biol Sci. 2021 Dec;28(12):7105-7116. doi: 10.1016/j.sjbs.2021.08.003. Epub 2021 Aug 8.
4
α-lipoic acid reduces hypertension and increases baroreflex sensitivity in renovascular hypertensive rats.
Molecules. 2012 Nov 9;17(11):13357-67. doi: 10.3390/molecules171113357.
5
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.
J Lipid Res. 2012 Mar;53(3):540-547. doi: 10.1194/jlr.M018010. Epub 2011 Dec 17.
6
Role of oxidant scavengers in the prevention of Ca²+ homeostasis disorders.
Molecules. 2010 Oct 15;15(10):7167-87. doi: 10.3390/molecules15107167.
本文引用的文献
1
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
Am J Med. 2009 Oct;122(10):962.e1-8. doi: 10.1016/j.amjmed.2009.03.030. Epub 2009 Aug 19.
2
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Diabetes Care. 2009 Mar;32(3):493-8. doi: 10.2337/dc08-1543. Epub 2008 Nov 4.
3
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
Diab Vasc Dis Res. 2008 Nov;5(4):319-35. doi: 10.3132/dvdr.2008.046.
4
Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet.
N Engl J Med. 2008 Jul 17;359(3):229-41. doi: 10.1056/NEJMoa0708681.
5
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
Am J Cardiol. 2008 May 15;101(10):1428-36. doi: 10.1016/j.amjcard.2008.02.092.
6
Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study.
Int J Obes (Lond). 2008 May;32 Suppl 2:S11-6. doi: 10.1038/ijo.2008.29.
7
Mechanism of action of niacin.
Am J Cardiol. 2008 Apr 17;101(8A):20B-26B. doi: 10.1016/j.amjcard.2008.02.029.
8
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
Lancet. 2008 Jan 12;371(9607):117-25. doi: 10.1016/S0140-6736(08)60104-X.
9
Exercise training amount and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise).
Am J Cardiol. 2007 Dec 15;100(12):1759-66. doi: 10.1016/j.amjcard.2007.07.027. Epub 2007 Oct 29.
10
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Clin Ther. 2007 Jul;29(7):1354-67. doi: 10.1016/j.clinthera.2007.07.018.
Zotero 插件